To improve decision-making and eliminate waste, every healthcare decision should be informed by the best scientific research derived from rigorous, proven methodologies
Real-World Evidence plays a significant role in how the pharmaceutical industry brings a brand to market. It can be used in assisting clinical trial designs, reviewing pricing structure and marketing strategy, understanding competitive threats and even determining new formulations, to name a few. Data should be strictly selected, validated and standardized before it can be analyzed. HEOR helps the pharmaceutical industry provide better healthcare services to address the needs of patients.
advanced statistical programming
advanced statistical programming
- Estimate size of disease population, prevalence and incidence rate
- Patient characteristics (age, gender, geographic region, insurance, comorbidities, commonly used treatment)
- Market profile
Burden of Illness
- Health care resource utilization (HCRU) – hospitalization, emergency room (ER) visits, office visits, specific treatment procedures and lab tests
- Direct medical and pharmacy cost
- Indirect cost due to loss of productivity
- Medication adherence and persistence
- Treatment switch patterns
- Line of therapy
- Dosing analysis
- Prescribing behavior
- Treatment effects comparison
health economics outcomes research insights
Subgroup identification searches for groups of patients that have an especially positive response to the drug of interest, and as a result can be useful for physicians when making more personalized prescribing decisions. What is subgroup identification and why use it?...
If analyzed correctly, compelling data can serve business needs and reveal commercial opportunities. The KMK Real World Evidence Dashboard is a customized client-centered approach to help biopharmaceutical companies reach intuitive conclusions faster, save significant...
KMK HEOR Principal Huanxue Zhou's latest manuscript: Healthcare resource utilization, treatment patterns, and cost of care among patients with thermal burns and inpatient autografting in two large privately insured populations in the United States. Highlights • Major...
The terms Real World Evidence (RWE) and Real World Data (RWD) appear more and more in industry discussions and within FDA reports. The pharma industry is embracing RWE and it is quickly becoming the next big thing in industry intelligence. FDA guidelines have been...
We all appreciate a good story. As researchers, however, we sometimes overlook the power of narrative in exploring one of the most basic topics in health care market research – the patient journey. When we rush to impose prefabricated schema on the patient's encounter...
Do you feel sluggish or lethargic most days? Are you susceptible to catching colds? If you blame the “daily grind” for why you’re feeling rundown, you might be overlooking a simple nutrient deficiency. Iron is needed to make hemoglobin — part of our red blood cells...
With the ever-increasing degree of digitalization of health records of various kinds, it has never been easier to track different facets of a patient’s journey. Not only it is now possible to trace all the different events associated with one particular medical...